Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
108814355 | 10881435 | 5 | F | 201502 | 20160826 | 20150303 | 20160906 | EXP | PHHY2010CA19119 | NOVARTIS | 52.62 | YR | M | Y | 0.00000 | 20160906 | MD | CA | CA |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
108814355 | 10881435 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | UNK | U | 19667 | |||||||||
108814355 | 10881435 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | U | 0 | 40 | MG | SUSPENSION | /month | |||||
108814355 | 10881435 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | U | 0 | 40 | MG | SUSPENSION | /month | |||||
108814355 | 10881435 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, QMO | U | 0 | 20 | MG | SUSPENSION | /month | |||||
108814355 | 10881435 | 5 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | U | 0 | 40 | MG | SUSPENSION | /month | |||||
108814355 | 10881435 | 6 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | U | 0 | 40 | MG | SUSPENSION | /month | |||||
108814355 | 10881435 | 7 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | 0 | 10 | MG | QD | |||||||
108814355 | 10881435 | 8 | C | DIABINESE | CHLORPROPAMIDE | 1 | Unknown | 250 MG, QD | U | 0 | 250 | MG | QD | ||||||
108814355 | 10881435 | 9 | C | COVERSYL /FRA/ | PERINDOPRIL | 1 | Unknown | 04 MG, UNK | U | 0 | 4 | MG | |||||||
108814355 | 10881435 | 10 | C | SUTENT | SUNITINIB MALATE | 1 | Unknown | 37.5 MG, QD | U | 0 | 37.5 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
108814355 | 10881435 | 1 | Pancreatic neuroendocrine tumour metastatic |
108814355 | 10881435 | 2 | Pancreatic neuroendocrine tumour metastatic |
108814355 | 10881435 | 7 | Pancreatic neuroendocrine tumour metastatic |
108814355 | 10881435 | 8 | Product used for unknown indication |
108814355 | 10881435 | 9 | Product used for unknown indication |
108814355 | 10881435 | 10 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
108814355 | 10881435 | HO |
108814355 | 10881435 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
108814355 | 10881435 | Bacterial infection | |
108814355 | 10881435 | Blood pressure decreased | |
108814355 | 10881435 | Blood pressure increased | |
108814355 | 10881435 | Body temperature decreased | |
108814355 | 10881435 | Dental caries | |
108814355 | 10881435 | Duodenal obstruction | |
108814355 | 10881435 | Fatigue | |
108814355 | 10881435 | Gingivitis | |
108814355 | 10881435 | Headache | |
108814355 | 10881435 | Hypersomnia | |
108814355 | 10881435 | Metastases to liver | |
108814355 | 10881435 | Pancreatic carcinoma | |
108814355 | 10881435 | Tooth infection | |
108814355 | 10881435 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
108814355 | 10881435 | 1 | 20100301 | 0 | ||
108814355 | 10881435 | 2 | 20100319 | 0 | ||
108814355 | 10881435 | 7 | 20110324 | 20120216 | 0 | |
108814355 | 10881435 | 10 | 201608 | 0 |